In the early phase of cardiac hypertrophy, the expression trend of miR-30a* and miR-214 were opposite, while XBP1 was increased, so we treated cardiomyocyte with miR-214 mimics and miR-30a* inhibitors (anti-30a*) to further test if down expression of miR-30a* reverses suppressive effect of miR-214 upregulation in XBP1 expression. The gene discussed is XBP1; the disease is cardiac hypertrophy.